• Aptar Pharma is an Outstanding Issue Sponsor in April’s ONdrugDelivery

    “Is Now the Time to Shake Up the pMDI Environment?” by Chris Baron, Director Business Development, Rx, EMEA at Aptar Pharma. This article explores how the use of propellants in pressurised metered dose inhalers has evolved – and how alternative propellants could be a catalyst for greater patient adherence. “Developing an In Vitro Dissolution and Release System for Orally Inhaled Drug Products” by Rob Price, Chief Scientific Officer, Nanopharm Ltd, an Aptar Pharma company. This article critiques regulatory routes for the development of generic OINDPs, runs through recent announcements and developments of note from regulators, and describes how Nanopharm has pioneered the concept of structural Q3 equivalence. “Be prepared. The Importance of Training and Onboarding Programs for Intranasal Rescue Therapies” by Joe Masci, Executive Director of Business Development Noble International, an Aptar Pharma company. With a recent resurgence in nasal drug repurposing, this article looks at the importance of training and onboarding for intranasal rescue therapies.

  • Aptar and Sonmol Partner to Develop Digital Platform for Respiratory-Related Therapies

    This collaboration will initially focus on bringing together connected drug delivery devices and the digital platform for asthma and chronic obstructive pulmonary disease (COPD). Aptar Pharma and Sonmol will work together on expanding Sonmol’s platform services to enable remote patient monitoring, improve patient and physician interactions, increase patient engagement and adherence, and improve health outcomes. The partnership will work with pharmaceutical and healthcare partners to accelerate the development, manufacturing, commercialization and supply of digital respiratory medicines, diagnostics and patient support services in China and other Asian markets for marketed and pipeline drugs. The collaboration significantly bolster’s Aptar’s digital health offerings in Asia by combining Aptar Pharma’s expertise in connected drug delivery device development, innovation and quality manufacturing together with Sonmol’s connected devices, data platform and patient management services. Stephan Tanda, Aptar President and CEO, stated, “We are pleased to partner with Sonmol to improve health outcomes by combining Aptar’s breadth of regulatory experience, quality focus and connected drug delivery device innovations with Sonmol’s patient adherence platform.” Xiangwei Gong, President of Aptar Asia, added, “We look forward to furthering digital respiratory medicines, diagnostics and patient support services in China and other Asian markets.” Sonmol, which is based in Shanghai, was founded in 2014 by Luffy Lv and a core team of software, algorithm and medical experts. Sonmol’s strategic focus is on chronic respiratory diseases, which is second largest disease category in China. Government initiatives to push for early detection and prevention measures for chronic respiratory diseases strengthen the case for Smart Inhalers and connected devices as platforms to improve health conditions in patients, rectify the use of medications, improve inhaler adherence and provide better treatment outcomes for patients. Added Luffy Lv, CEO of Sonmol, “Aptar Pharma has a well-established position worldwide in drug delivery technologies across the whole value chain. Collaborating with Aptar will help us expand and speed up clinical application and commercialization of Sonmol’s innovative products. I look forward to more in-depth and innovative exploration and collaboration between Aptar and Sonmol in the field of drug and disease digital management in China and worldwide.” Gael Touya, President of Aptar Pharma, commented, “This partnership with Sonmol continues to develop our strategy in digital health, building platforms for customers and their patients worldwide. We look forward to our future collaboration.” Aptar Pharma and Sonmol will co-build the ecosystem of connected healthcare devices and services for China and other markets, and collaborate on device development and manufacturing for local and global markets. Sonmol will focus on data and software development for China.

  • The 53rd manufacturing bean jam basic course

    This event was held for customers who purchased Kajiwara's confectionery machine. After learning the theory of bean jam, in the 1st floor test room, we practiced the small unmanned bean jam line hybrid hybrid machine electromagnetic steam production using the electromagnetic steam and the unmanned bean jam production in the unmanned bean jam unit. I was able to finish it.

  • FOBA supports manufacturers with webcasts and flexible marking solutions during the crisis

    FOBA supports manufacturers with webcasts and flexible marking solutions during the crisis Fast provision, uncomplicated financing models and extended service make it easier to cope with production peaks In FOBA’s webinar series, laser marking experts offer direct part marking backgrounds and practical application knowledge Laser marking ensures safe traceability as well as counterfeit protection Selmsdorf, April 2020 – FOBA Laser Marking + Engraving (Alltec GmbH) offers support for manufacturers that need to cope with special requirements in the Corona crisis.

  • Expanded Capacity for Vial & Syringe Packaging at Keystone Folding Box Co.

    Amid increased demand from biologics and vaccines sectors,
    Company invests in additional die cutting and gluing machinery,
    expanding production capacity and allowing for expedited turnaround.

    Newark, NJ – Keystone Folding Box Co., a designer and manufacturer of paperboard packaging solutions, has incorporated new die cutting and gluing equipment into its production facility. The infrastructure investment increases the company’s production capacity of vial and syringe packaging by 25%, and accommodates shorter lead-times.

  • Legacy Pharmaceutical Packaging Acquires Multiple Blister Production Lines from McKesson RxPak

    Company also adds bottling and pouching equipment
    in anticipation of heightened demand.

  • Messe Frankfurt to focus on highlighting urgent anti-counterfeiting measures in wake of Covid-19

    As demand for medical supplies soars worldwide in the fight against Covid-19, there is a parallel risk of substandard and counterfeit medicines in the global market. With India being one of the world's largest producers of medical supplies, there is an urgent need to bring in strong anti-counterfeiting measures which will be addressed at Messe Frankfurt’s upcoming conference - Pharmasafe India 2020.

  • analytica Anacon India, India Lab Expo and Pharma Pro&Pack Expo host an exclusive webinar on the topic “Time to Collaborate, Co-operate and Innovate to face challenges in Pharma Industry”

    On 16th of April 2020, Messe Muenchen India –organiser of leading trade fairs like analytica Anacon India, India Lab Expo and Pharma Pro & Pack Expo in association with Indian Pharma Machinery Manufacturers Association (IPMMA) conducted an extensive webinar focused on the pharmaceutical industry. The webinar was well attended by over 400+ participants from not only India but also countries like Germany, Italy, UAE and Nepal.
    The webinar was also supported by IAIA (Indian Analytical Instruments Association).

  • Counterfeit Protection from Analogue to Digital

    The whirring sound of the rotary dial telephone has long become a thing of the past. Like phones, many other devices and functions have managed the leap into the digital age. Anti-counterfeiting technology is a case in point: Color-shifting inks or classic holograms known from paper money are increasingly complemented by digital security features that can be read using smartphones. These features enable automatic authentication and offer a wide variety of added value. The future of innovative anti-counterfeiting labels lies in the development of such digital solutions.

  • Visionary Multi-Layer Film Recycling Avoids Production Waste

    Coperion Delivers Innovative Closed-Loop Solution.

  • Pages